Key facts
- This page summarizes Junli He's Form 4 filing for Biostage, Inc. (HRGN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Jul 2022, 17:48.
Junli He - 29 Jun 2022 Form 4 Insider Report for Biostage, Inc. (HRGN)
- Reporting relationship
- Director
- Issuer ticker
- HRGN
- Reported as of
- 29 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Jul 2022, 17:48:58 UTC
- Prior SEC filing
- 20 May 2022
- Next SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chad Porter, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Junli He filed Form 4 for Biostage, Inc. (HRGN) on 01 Jul 2022.
Change
- Previous filing in this sequence was filed on 20 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BSTG
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +6,241
- Change %
- Price
- $0.000000
- Shares after
- 6,241
- Date
- 29 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.01 per share
- Underlying amount
- 6,241
- Exercise price
- $4.65
- Footnotes
- F1
BSTG
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +5,016
- Change %
- Price
- $0.000000
- Shares after
- 5,016
- Date
- 29 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.01 per share
- Underlying amount
- 5
- Exercise price
- $4.65
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 29, 2022, December 29, 2022, March 29, 2023 and June 29, 2023.
Footnote F2
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2022, September 30, 2022 and December 31, 2022.
SEC remarks
This form has been signed under power of attorney.